We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
+$27.8M
Cap. Flow %
7.12%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
1
PUT
uniQure
QURE
$3.03B
$17.5M 4.48%
+300,000
New +$5.45M
REGN icon
2
Regeneron Pharmaceuticals
REGN
$78.5B
$17M 4.34%
30,160
+24,553
+438% +$13.9M
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$13.3M 3.41%
+20,000
New +$12.8M
JAZZ icon
4
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
$13.2M 3.37%
100,000
+50,000
+100% +$6M
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$12M 3.07%
177,330
-106,822
-38% -$7.92M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.6B
$11.5M 2.95%
212,877
+20,000
+10% +$1.14M
VKTX icon
7
CALL
Viking Therapeutics
VKTX
$3.7B
$10.6M 2.72%
+405,100
New +$12.1M
AGIO icon
8
CALL
Agios Pharmaceuticals
AGIO
$1.79B
$8.92M 2.28%
222,100
+100,000
+82% +$3.76M
RNAM
9
CALL
DELISTED
Avidity Biosciences
RNAM
$8.72M 2.23%
+200,100
New +$8.09M
INCY icon
10
CALL
Incyte
INCY
$24.2B
$8.48M 2.17%
+100,000
New +$7.9M
NTLA icon
11
CALL
Intellia Therapeutics
NTLA
$1.49B
$8.12M 2.08%
+470,200
New +$5.79M
BMY icon
12
CALL
Bristol-Myers Squibb
BMY
$133B
$8.12M 2.08%
+180,000
New +$8.41M
PCVX icon
13
Vaxcyte
PCVX
$7.81B
$7.86M 2.01%
218,285
+20,000
+10% +$663K
LLY icon
14
PUT
Eli Lilly
LLY
$1.02T
$7.63M 1.95%
10,000
-10,700
-52% -$7.96M
CRSP icon
15
CALL
CRISPR Therapeutics
CRSP
$4.73B
$7.26M 1.86%
112,000
– –
BBIO icon
16
CALL
BridgeBio Pharma
BBIO
$15.7B
$6.82M 1.75%
131,400
– –
SLNO
17
PUT
DELISTED
Soleno Therapeutics
SLNO
$6.76M 1.73%
+100,000
New +$7.41M
JAZZ icon
18
PUT
Jazz Pharmaceuticals
JAZZ
$15.9B
$6.59M 1.69%
+50,000
New +$6M
IONS icon
19
CALL
Ionis Pharmaceuticals
IONS
$8.6B
$6.54M 1.67%
+100,000
New +$4.88M
INDV icon
20
Indivior Pharmaceuticals
INDV
$4.73B
$6.13M 1.57%
+254,252
New +$5.32M
BMY icon
21
Bristol-Myers Squibb
BMY
$133B
$5.86M 1.5%
+130,000
New +$6.07M
MNKD icon
22
CALL
MannKind Corp
MNKD
$1.21B
$5.58M 1.43%
1,039,500
+519,600
+100% +$2.28M
NVO
23
PUT
Novo Nordisk
NVO
$208B
$5.55M 1.42%
+100,000
New +$5.85M
ASND icon
24
Ascendis Pharma A/S
ASND
$16B
$5.48M 1.4%
+27,572
New +$5.14M
PRAX icon
25
PUT
Praxis Precision Medicines
PRAX
$8.58B
$5.3M 1.36%
+100,000
New +$4.85M
1
2 3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners deployed $27.8M of net new capital in Q3 2025, opening 75 new positions and adding to 15 existing holdings. Its largest new stake was Bristol-Myers Squibb: 130,000 shares worth $5.86M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 49% a quarter earlier.

On the sell side, the largest reduction was TG Therapeutics, an estimated $10.2M trimmed.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.